SecBot SecBot
SECBOTREPLAY Home › Report › TOVX

TOVX · Theriva Biologics announced positive results from its VIRAGE Phase 2b…

Theriva Biologics, Inc. · 8-K filed Apr 17, 2026 at 16:15 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 17, 2026 at 16:15 ET

Theriva Biologics announced positive results from its VIRAGE Phase 2b clinical trial, showing improved overall survival and progression-free survival in metastatic pancreatic cancer patients treated with VCN-01 plus chemotherapy. The data, to be presented at the AACR 2026 meeting, supports an immune-mediated mechanism of action and demonstrates consistent benefits across subgroups, including those with liver metastases.

  • Patients receiving VCN-01 + chemotherapy had improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone.
  • The survival benefit was maintained across subgroups, including patients with liver metastases.
  • Patients who received a second dose of VCN-01 showed a greater benefit in OS and PFS.
  • The company has achieved alignment with both the FDA and EMA on a proposed pivotal Phase 3 trial.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access